COMMUNIQUÉS West-GlobeNewswire

MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
12/03/2026
Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated [...]
Century Therapeutics Reports Full Year 2025 Financial Results and Business Updates
12/03/2026
CNTY-813, lead beta islet cell therapy program as a potential functional cure for type 1 diabetes, in Investigational New Drug (IND)-enabling studies; IND submission expected in 4Q 2026 to support anticipated initial [...]
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
12/03/2026
- Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma - - Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential [...]
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
12/03/2026
Conference Call and Webcast Scheduled for Friday, March 20 at 8:30am ET MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that it will report [...]
Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
12/03/2026
Working to advance TSC-related epilepsy program, with a focus on capital efficiency AUSTIN, Texas, March 12, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana [...]
BioVie Announces Abstract Accepted for Presentation at AD/PD 2026
12/03/2026
CARSON CITY, Nev., March 12, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases [...]
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
12/03/2026
Award recognizes leading chronic kidney disease advocates WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and [...]
Marine Biologics Unveils SeaTex™ For Clean Label Nutritional Design And Performance
12/03/2026
Novel single-ingredient seaweed powder designed for high-performance stabilization dramatically simplifies product formulations with zero additives or synthetic ingredients BERKELEY, Calif., March 12, 2026 (GLOBE [...]
Curanex Expands Scientific Advisory Board With Two Distinguished Researchers
12/03/2026
New Appointments Bring Deep Expertise in Immunology and Infectious Disease to Advance IND Submission and Intellectual Property Strategy Jericho, New York, March 12, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc [...]
PracticeLink Launches 2026 Webinar Series for Healthcare Recruiters
12/03/2026
ST. LOUIS and HINTON, West Virginia, March 12, 2026 (GLOBE NEWSWIRE) -- PracticeLink , the nation’s most trusted physician recruitment resource and home of the most widely used online physician job board, is pleased to [...]
Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy
12/03/2026
Reduced progression of myocardial fibrosis measured by LGE on cardiac MRI (p=0.022) Significant improvement in LVEF versus placebo in patients with baseline cardiomyopathy (p=0.017) Global Statistical Test (GST) [...]
Trinity Biotech Begins Rollout of Innovative Glucose Monitoring System In Key Market Following Regulatory Approval of Next-Generation Premier Hb9210 HbA1c Column System
12/03/2026
Company begins roll out of innovative diabetes care HbA1c column system in Brazil Commercial leadership strengthened with key appointment DUBLIN, March 12, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a [...]
NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026
12/03/2026
CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]
Centre for Neuro Skills Appoints Curtis Shipman as Chief Information Officer
12/03/2026
Technology leader brings 15+ years of experience in enterprise infrastructure, cybersecurity and digital transformation to national brain injury rehabilitation provider BAKERSFIELD, Calif., March 12, 2026 (GLOBE [...]
Longeveron to Report 2025 Full-Year Financial Results and Host Conference Call on March 17, 2026
12/03/2026
MIAMI, March 12, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, [...]
Signati™ Medical Announces Dr. LeRoy Jones Has Been Appointed as a Professor of Urology at the University of Texas San Antonio
12/03/2026
Providence, RI, March 12, 2026 (GLOBE NEWSWIRE) -- Dr. Jones is widely regarded as one of the most accomplished prosthetic surgeons in the nation, with over 30 years of clinical experience. Dr. Jones has performed over [...]
PROCEPT BioRobotics® Announces International Launch of the HYDROS® Robotic System, Expanding Global Access to AI-Enabled Aquablation® Therapy
12/03/2026
UK marks first international launch of the HYDROS Robotic System, with additional international expansion planned in 2026 SAN JOSE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT), today [...]
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products
12/03/2026
Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio Transaction expected to [...]
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
12/03/2026
Root-Cause Attack. Chemo Sensitization. Safer Profile. MELBOURNE, Australia, March 12, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on [...]

Pages